Close Menu

NEW YORK (GenomeWeb News) – South Korean firm Boram Pharm has filed a patent infringement suit in the US against Life Technologies alleging infringement of a patent covering technology for producing recombinant viruses.

The suit was filed last week in the US District Court for the District of Delaware. Boram claims that Life Technologies is infringing US Patent No. 7,319,001, titled "High throughput system for producing recombinant viruses using site-specific recombination." The patent was issued on Jan. 15, 2008 to Neurogenex, which is now owned by Boram.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.